COL7A1 and recessive dystrophic epidermolysis bullosa: In 2020, the European Medicines Agency granted the orphan drug status to the drug developed on the basis of CRISPR/Cas9-mediated excision of the 80th exon of the COL7A1 gene bearing a mutation as the potential new therapy for RDEB patients [33,34].